BACK

CompuVax, Inc. and The Scripps Research Institute enter into an exclusive research and license agreement

04.01.15

CompuVax, Inc. and The Scripps Research Institute enter into an exclusive research and license agreement

La Jolla, April 1, 2015

CompuVax, Inc. and The Scripps Research Institute (TSRI) have entered into an exclusive research and license agreement for the research and development of vaccines with proprietary technology at Bill Schief's laboratory.

The research at TSRI will focus on respiratory syncytial virus, metapneumovirus and universal influenza antigens and on additional targets not disclosed. It will also include the development of a nanoparticle platform for multivalent display of these antigens.

CompuVax, Inc. will be the exclusive licensee worldwide of antigens and nanoparticles engineered during the research program.

This agreement is expected to be renewed yearly over several years.